Natural history and clinical features of aspirin-exacerbated respiratory disease

被引:55
作者
Fahrenholz, JM [1 ]
机构
[1] Allergy & Asthma Specialists, Nashville, TN 37205 USA
[2] Scripps Clin, La Jolla, CA USA
[3] Green Hosp, La Jolla, CA USA
关键词
aspirin-sensitive asthma; aspirin triad; nonsteroidal antiinflammatory drugs; adverse reactions;
D O I
10.1385/CRIAI:24:2:113
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinosinusitis, nasal polyposis, asthma and precipitation of asthma, and rhinitis attacks after ingestion of aspirin (ASA) and most other nonsteroidal antiinflammatory drugs (NSAIDs). Although precipitation of asthma attacks by ingestion of ASA and other NSAIDs is considered a hallmark of the syndrome, the respiratory mucosal inflammatory disease process begins and continues in the absence of ongoing or even intermittent exposure to ASA or NSAIDs. The typical patient with AERD is an adult who develops refractory chronic rhinitis in the third or fourth decade of life. The chronic rhinitis evolves into chronic eosinophilic rhinosinusitis with associated nasal polyposis. Anosmia. appears in most patients. CT of the sinuses most often demonstrates pansinusitis and patients often undergo multiple sinus operations resulting in only limited temporary benefit. During the evolution of the sinus disease persistent asthma develops. Finally, if patients are exposed to ASA or NSAIDs acute respiratory reactions begin to occur. Despite subsequent avoidance of ASA and other NSAIDs, the respiratory mucosal inflammatory disease persists, often requiring systemic corticosteroids for control of both upper- and lower-respiratory tract symptoms. Adequate control of asthma can often only be accomplished with the simultaneous control of the associated rhinosinusitis. With few exceptions, once AERD develops it remains for the remainder of the patient's life..
引用
收藏
页码:113 / 124
页数:12
相关论文
共 72 条
[1]   EFFECT OF SODIUM CROMOGLYCATE IN PREVENTING ASPIRIN INDUCED BRONCHOSPASM [J].
BASOMBA, A ;
ROMAR, A ;
PELAEZ, A ;
VILLALMANZO, IG ;
CAMPOS, A .
CLINICAL ALLERGY, 1976, 6 (03) :269-275
[2]   Rofecoxib safe in NSAID hypersensitivity [J].
Berges-Gimeno, MP ;
Camacho-Garrido, E ;
García-Rodriguez, RM ;
Alfaya, T ;
García, CM ;
Hinojosa, M .
ALLERGY, 2001, 56 (10) :1017-1018
[3]  
BERGESGIMENO M, 2002, IN PRESS CLIN EXP AL
[4]  
BERGESGIMENO M, 2002, IN PRESS ANN ALLERGY
[5]   TRYPTASE AND HISTAMINE-RELEASE DURING ASPIRIN-INDUCED RESPIRATORY REACTIONS [J].
BOSSO, JV ;
SCHWARTZ, LB ;
STEVENSON, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 88 (06) :830-837
[6]   IDIOSYNCRASY TO PYRAZOLONE DRUGS [J].
CZERNIAWSKAMYSIK, G ;
SZCZEKLIK, A .
ALLERGY, 1981, 36 (06) :381-384
[7]   Treatment of aspirin-intolerant asthma with antileukotrienes [J].
Dahlén, B .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) :S137-S141
[8]   Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics [J].
Dahlén, B ;
Nizankowska, E ;
Szczeklik, A ;
Zetterström, O ;
Bochenek, G ;
Kumlin, M ;
Mastalerz, L ;
Pinis, G ;
Swanson, LJ ;
Boodhoo, TI ;
Wright, S ;
Dubé, LM ;
Dahlén, SE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (04) :1187-1194
[9]   Improvement of asprinin-intolerant asthma by montelukast, a leukotriene antagonist -: A randomized, double-blink, placebo-controlled trial [J].
Dahlén, SE ;
Malmström, K ;
Nizankowska, E ;
Dahlén, B ;
Kuna, P ;
Kowalski, M ;
Lumry, WR ;
Picado, C ;
Stevenson, DD ;
Bousquet, J ;
Pauwels, R ;
Holgate, ST ;
Shahane, A ;
Zhang, J ;
Reiss, TF ;
Szczeklik, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (01) :9-14
[10]   ASPIRIN AND SUBTYPES OF ASTHMA - RISK FACTOR-ANALYSIS [J].
FALLIERS, CJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1973, 52 (03) :141-147